The U.S. Food and Drug Administration has approved Atzumi™ (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults. Developed by Satsuma Pharmaceuticals, Atzumi™ is the first and only DHE nasal powder to receive FDA approval, offering a fast-acting and easy-to-use delivery system designed to meet the real-world needs of migraine sufferers. DelRicht Research played a key role in the clinical trial that supported this approval.

DelRicht Research Clinical Trial Leadership Across the United States

DelRicht Research supported the approval through a multi-site clinical trial effort led by the following principal investigators:

Dr. Taylor Sanders – Neighborhood Health, Prairieville, LA
Dr. Patrick Dennis – Touro Medical Center, New Orleans, LA
Dr. Melita Tate – Grassroots Healthcare, Tulsa, OK
Dr. Sean Kerby – Gulfport Memorial, Gulfport, MS
Dr. Robert Springer – Springer Wellness and Restorative Health, Atlanta, GA
Dr. Rachael Murphy – The Murphy Clinic, Mandeville, LA

Their contributions were key in evaluating Atzumi’s pharmacokinetics, safety, and tolerability across a diverse population of patients with migraine.

Meeting an Urgent Need

Migraine affects an estimated 40 million Americans, often disrupting work, relationships, and quality of life. While DHE has been used for decades in migraine treatment, existing options like injections or liquid nasal sprays have posed challenges due to complicated administration. Atzumi™ uses a proprietary powder formulation and intranasal device that simplifies use, enabling fast absorption and sustained relief.

A Promising Step Forward

“The approval of Atzumi™ is an exciting milestone in migraine care,” said Marshall Morris, Partner at DelRicht Research. “Our investigators’ work played a critical role in bringing this option to market, and we’re proud to support a therapy that’s effective, easy to use, and designed with patients in mind.”

“Our investigators’ work played a critical role in bringing this option to market, and we’re proud to support a therapy that’s effective, easy to use, and designed with patients in mind.”

— Marshall Morris, Partner at DelRicht Research

Physician Perspectives on Innovation

“Migraine can be incredibly disruptive to daily life,” added Dr. Patrick Dennis, a lead investigator in the trial. “Atzumi™ offers a new way to manage those attacks quickly and reliably, even when taken later in an episode. We’re proud to support progress that gives patients greater flexibility and better outcomes.”

“Atzumi™ offers a new way to manage those attacks quickly and reliably, even when taken later in an episode. We’re proud to support progress that gives patients greater flexibility and better outcomes.”

— Dr. Patrick Dennis, Principal Investigator at DelRicht Research

A New Era for Migraine Treatment

Atzumi’s approval reinforces the importance of clinical research in delivering patient-friendly innovations. With its convenient nasal powder format, Atzumi™ may be especially valuable for patients seeking effective relief without the burden of injectables or complex administration.
To learn more about the FDA approval and product details, read Satsuma’s full press release. DelRicht Research remains committed to advancing innovative therapies through site-level excellence and trusted research partnerships.

Congratulations to the team at Satsuma on this exciting achievement, and thank you to our dedicated teams and trial participants who helped make this possible!